v3.26.1
Equity Transactions (Tables)
6 Months Ended
Jun. 30, 2026
Equity [Abstract]  
Schedule of Common Stock and Pre-funded Warrants

 

Date  Common
Stock
   Pre-funded
Warrants
   Gross
Proceeds
 
April 2, 2025   27    1   $28 
June 9, 2025   127    25    152 
June 27, 2025   5    -    5 
    159    26   $185 
Schedule of Warrants Outstanding

As of June 30, 2026, the Company had the following warrants outstanding:

 

   Warrants Outstanding   Exercise
Price
   Expiration
Date
  Classification
Q1-22 Warrants   914   $14,329.47   09/09/27  Liability
December 2022 Warrants   377   $537.26   06/02/28  Equity
Milestone Warrants   840,000   $17.00   *  Equity
Prefunded warrants   15,014   $1.88   None  Equity
    856,305            

 

*The Milestone Warrants expire the earlier of (i) the five-year anniversary of the original issuance date or (ii) the 180th calendar day following the public release by the Company of clinical trial data from the first cohort of the Phase 1 study of ERNA-101.
Schedule of Warrants Activity

The following table shows the warrant activity from January 1, 2026 through June 30, 2026:

 

   Outstanding
January 1, 2026
   Granted   Exercised   Outstanding
June 30, 2026
 
Q1-22 Warrants   914    -    -    914 
December 2022 Warrants   377    -    -    377 
Milestone Warrants   -    840,000    -    840,000 
Prefunded warrants   15,320    80,000    (80,306)   15,014 
Total   16,611    920,000    (80,306)   856,305